HT
Hiroki Takai
Director, Investment Group, UK Office at Global Brain Corporation
London, England
Overview
Hiroki Takai is a Biotech VC based in London, with a background in Venture Capital and expertise in areas such as Epigenetics and Cancer Research. As the Director at Global Brain Corporation and having invested in companies like Zafrens and Switch Therapeutics, he has demonstrated a strong track record of successful investments in the biotechnology sector.
With experience at Eli Lilly and Company and a diverse educational background including a PhD and MBA, Hiroki Takai has established himself as a key player in the biotech investment landscape, focusing on sectors such as Drug Delivery and Therapeutics.
Work Experience
Director, Investment Group, UK Office
2023 - Current
I am responsible for Life Science investments, including strategy development, investment execution, and growth support. As the first life science investor outside of Japan at Global Brain, I build a tangible network locally and globally and evaluate opportunities in the healthcare sector. I also fundraise and manage the relationship with our Limited Partners.
Principal, Investment Group, UK Office
2022 - 2023
Educational Leave
2020 - 2022
London Business School, MBA Class of 2022
Senior Associate, Lilly New Ventures
2021 - 2021
Senior Associate, Japan Drug Development and Medical Affairs
2016 - 2020
Eli Lilly engages in the discovery, development, manufacture, and sale of pharmaceutical products.
Raised $6,500,000.00.
Consultant
2020 - 2022
My first start-up vibes. Advisory role on R&D from a biochemist perspective.
Project Manager
2021 - 2022
Forecasting and advisory role at the Economist Group through research and analysis of the Asian Pharmaceutical and CDMO market.
Research Fellow
2015 - 2016
Education
Master of Business Administration - MBA
2020 - 2022
Doctor of Philosophy (Ph.D.)
2012 - 2015
Master's degree
2010 - 2012
Bachelor's degree
2006 - 2010